179 related articles for article (PubMed ID: 38175471)
1. European Practice for CDI Treatment.
Fitzpatrick F; Brennan R; van Prehn J; Skally M; Brady M; Burns K; Rooney C; Wilcox MH
Adv Exp Med Biol; 2024; 1435():57-84. PubMed ID: 38175471
[TBL] [Abstract][Full Text] [Related]
2. The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis.
Stabholz Y; Paul M
Clin Microbiol Infect; 2024 Jan; 30(1):51-58. PubMed ID: 37690610
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Treatment Regimens for Clostridioides difficile Infection: An Evaluation of the 2018 Infectious Diseases Society of America Guidelines.
Rajasingham R; Enns EA; Khoruts A; Vaughn BP
Clin Infect Dis; 2020 Feb; 70(5):754-762. PubMed ID: 31001619
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR).
Bouza E; Aguado JM; Alcalá L; Almirante B; Alonso-Fernández P; Borges M; Cobo J; Guardiola J; Horcajada JP; Maseda E; Mensa J; Merchante N; Muñoz P; Pérez Sáenz JL; Pujol M; Reigadas E; Salavert M; Barberán J
Rev Esp Quimioter; 2020 Apr; 33(2):151-175. PubMed ID: 32080996
[TBL] [Abstract][Full Text] [Related]
5. Clostridioides Difficile: A Concise Review of Best Practices and Updates.
Yakout A; Bi Y; Harris DM
J Prim Care Community Health; 2024; 15():21501319241249645. PubMed ID: 38726585
[TBL] [Abstract][Full Text] [Related]
6. Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of
Hernando-Gozalo M; Rescalvo-Casas C; Seijas-Pereda L; Cuadros-González J; Pérez-Tanoira R
Heliyon; 2024 May; 10(10):e30742. PubMed ID: 38803946
[TBL] [Abstract][Full Text] [Related]
7. Navigating changes in
Durham SH; Le P; Cassano AT
J Manag Care Spec Pharm; 2020 Dec; 26(12-a Suppl):S3-S23. PubMed ID: 33533699
[No Abstract] [Full Text] [Related]
8. Fighting against Clostridioides difficile infection: Current medications.
Quan M; Zhang X; Fang Q; Lv X; Wang X; Zong Z
Int J Antimicrob Agents; 2024 Jul; 64(1):107198. PubMed ID: 38734214
[TBL] [Abstract][Full Text] [Related]
9. Clostridioides difficile infections; new treatments and future perspectives.
Normington C; Chilton CH; Buckley AM
Curr Opin Gastroenterol; 2024 Jan; 40(1):7-13. PubMed ID: 37942659
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Competing Treatment Strategies for Clostridium difficile Infection: A Systematic Review.
Le P; Nghiem VT; Mullen PD; Deshpande A
Infect Control Hosp Epidemiol; 2018 Apr; 39(4):412-424. PubMed ID: 29463339
[TBL] [Abstract][Full Text] [Related]
11.
Al Naser Y; AlGashami M; Aljashaami L
Prz Gastroenterol; 2024; 19(1):1-5. PubMed ID: 38571533
[No Abstract] [Full Text] [Related]
12. Review article: The epidemiology and management of Clostridioides difficile infection-A clinical update.
Clarke LM; Allegretti JR
Aliment Pharmacol Ther; 2024 Jun; 59(11):1335-1349. PubMed ID: 38534216
[TBL] [Abstract][Full Text] [Related]
13. Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CD.
Walsh L; Lavelle A; O'Connor PM; Hill C; Ross RP
Gut Microbes; 2024; 16(1):2342583. PubMed ID: 38722061
[TBL] [Abstract][Full Text] [Related]
14. Effective treatment of Clostridioides difficile infection improves survival and affects graft-versus-host disease: a multicenter study by the Polish Adult Leukemia Group.
Piekarska A; Sadowska-Klasa A; Mensah-Glanowska P; Sobczyk-Kruszelnicka M; Drozd-Sokołowska J; Waszczuk-Gajda A; Kujawska J; Wilk M; Tomaszewska A; Zaucha JM; Giebel S; Gil L
Sci Rep; 2024 Mar; 14(1):5947. PubMed ID: 38467719
[TBL] [Abstract][Full Text] [Related]
15. Probiotics: insights and new opportunities for
Pal R; Athamneh AIM; Deshpande R; Ramirez JAR; Adu KT; Muthuirulan P; Pawar S; Biazzo M; Apidianakis Y; Sundekilde UK; de la Fuente-Nunez C; Martens MG; Tegos GP; Seleem MN
Crit Rev Microbiol; 2023 May; 49(3):414-434. PubMed ID: 35574602
[No Abstract] [Full Text] [Related]
16. Emerging therapies for Clostridium difficile infection - focus on fidaxomicin.
Chaparro-Rojas F; Mullane KM
Infect Drug Resist; 2013; 6():41-53. PubMed ID: 23843696
[TBL] [Abstract][Full Text] [Related]
17. The clinical effectiveness of Fidaxomicin compared to Vancomycin in the treatment of Clostridioides difficile infection, a single center real-world experience.
Alsoubani M; Chow JK; Rodday AM; McDermott LA; Walk ST; Kent DM; Snydman DR
J Infect Dis; 2024 May; ():. PubMed ID: 38779889
[TBL] [Abstract][Full Text] [Related]
18. Guideline for the management of
Patel P; Robinson PD; Fisher BT; Phillips R; Morgan JE; Lehrnbecher T; Kuczynski S; Koenig C; Haeusler GM; Esbenshade A; Elgarten C; Duong N; Diorio C; Castagnola E; Beauchemin MP; Ammann RA; Dupuis LL; Sung L
EClinicalMedicine; 2024 Jun; 72():102604. PubMed ID: 38680517
[TBL] [Abstract][Full Text] [Related]
19. [Fulminant Clostridioides difficile infection during treatment with FLT3 inhibitor for acute myeloid leukemia].
Yamamoto J; Watanabe O; Sako T; Takagi S; Kaji D; Taya Y; Nishida A; Yamamoto H; Asano-Mori Y; Yamamoto G; Araoka H; Uchida N
Rinsho Ketsueki; 2024; 65(3):153-157. PubMed ID: 38569858
[TBL] [Abstract][Full Text] [Related]
20. Secondary prophylaxis for Clostridioides difficile infection for patients on non-C. difficile antibiotics: a retrospective cohort study.
Najjar-Debbiny R; Barnett-Griness O; Arbel A; Cohen S; Weber G; Amar M; Yassin R; Greenfeld I; Shehadeh S; Saliba W
Microbes Infect; 2024 May; ():105349. PubMed ID: 38719086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
